A Great Success: H2020 Clinical Trials Training on 15 March 2017 in Brussels
In the frame of the EC-funded project Fit for Health 2.0, Eurice had the pleasure to design, organise and moderate an international training on clinical trials in H2020 projects. 45 participants from 12 European countries representing different organisations such as universities, research institutes, industry, foundations and NCPs attended the training.
Following a general introduction on clinical trials by Dr Birte Kretschmer from Eurice, the training tackled key issues to be considered when planning and implementing clinical trials in H2020 projects. Experienced experts from the European Commission and running H2020 projects shared their knowledge, know-how and best practices.
Dr Cornelius Schmaltz and Dr Mark Goldammer from the DG Research & Innovation, Health Research-Strategy summarised the challenges in H2020 clinical trials from the EC’s point of view. In addition, Dr Christine Kubiak from ECRIN provided detailed information on the planning of a multinational H2020 clinical trial addressing questions such as how to calculate budgets or to set a well-defined time frame for clinical trials.
Prof. Jens Kastrup, coordinator of the H2020 SCIENCE project, introduced the project’s clinical trial and gave insights into ethical aspects and approval procedures complemented by practical experiences on the Voluntary Harmonization Procedure submission. Another case study presented by Dr Corinna Engel focused on the organisation of the overall data management as well as documentation and monitoring within the multinational, multicenter clinical study of the H2020 project Albino.
Each presentation was followed by a lively Q&A session giving participants the opportunity to ask their individual questions and further discuss crucial issues. The feedback received from attendees was very positive, reflected by statements such as “Great idea to have this event about an important theme that attracts many participants” or “The use of case studies was very useful”. The information provided during the event will surely serve as a good basis for planning and implementing H2020 clinical trials.
All presentations are available on the event page.